My5-FU regulatory update

The U.K.’s NICE issued final guidance concluding there is insufficient evidence to determine whether Saladax’s My5-FU diagnostic test is a clinically and cost-effective test to guide dose adjustment of 5-fluorouracil (5-FU) chemotherapy in patients with colorectal, head and neck, stomach and pancreatic cancers. NICE recommended further research to generate more evidence about its benefits. The guidance is in line with draft guidance. ...